Company news

Everest Medicines Ltd. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Everest Medicines to Announce 2025 Interim Results on August 29, 2025

August 11, 2025

Everest Medicines Announces Full Approval of NEFECON® in Taiwan

August 6, 2025

Everest Medicines Expands Strategic Investment in I-MAB

August 1, 2025

Everest Medicines Announces Share Placement to Raise Approximately HK$1,572.50 Million

July 24, 2025

Everest Medicines Showcases Breakthroughs in Proprietary AI-Powered mRNA Platform at 2025 R&D Day Held in Shanghai

July 4, 2025

Everest Medicines Announces Updated Positive Results in Preliminary Analysis of Phase 1b/2a Clinical Trial of EVER001, a Novel BTK Inhibitor for the Treatment of Primary Membranous Nephropathy

July 2, 2025

Everest Medicines to Host Virtual Nephrology-Focused KOL Event on June 30, 2025

June 26, 2025

Everest Medicines Announces Official Publication of the Specifications for Antimicrobial Susceptibility Testing of Eravacycline (2025)

June 22, 2025

Everest Medicines Announces Successful Release of First Clinical Batch of Tumor-Associated Antigen Vaccine EVM14 at Jiashan Manufacturing Site

June 20, 2025

Everest Medicines Presents Positive Results in Preliminary Analysis of Phase 1b/2a Clinical Trial of Novel BTK Inhibitor EVER001 at the 62nd Congress of the European Renal Association

June 9, 2025

NEFECON®: New Results at ERA 2025 Demonstrate Treatment Benefit of the 'Treat Early' Strategy

June 6, 2025

Everest Medicines Announces NEFECON® Inclusion in China's Clinical Practice Guideline for IgA Nephropathy and IgA Vasculitis in Chinese Adults (For Public Review)

May 22, 2025

Everest Medicines Announces NMPA Full Approval of NEFECON® for the Treatment of Primary Immunoglobulin A nephropathy (IgAN) in Adults at Risk of Disease Progression

May 6, 2025

Everest Medicines Announces New Drug Application Approval of VELSIPITY® for Adults with Moderately to Severely Active Ulcerative Colitis in Hong Kong

April 29, 2025

Everest Medicines Announces the "B" Marker Removal from Company's Stock Code, Effective May 2, 2025

April 27, 2025

Everest Medicines Announces Approval of "B" Marker Removal from Company's Stock Code by the Hong Kong Stock Exchange

April 21, 2025

Everest Medicines Announces Financial Results for Full Year Ended December 31, 2024

March 25, 2025

Everest Medicines Announces FDA Clearance of IND Application for Tumor-Associated Antigen Vaccine EVM14

March 23, 2025

Everest Medicines Announces First Patient Dosed with EVM16, Its First Internally Developed Personalized mRNA Cancer Vaccine

March 6, 2025

Everest Medicines to Hold Investor Calls with Updates on mRNA Therapeutic Vaccine Programs

February 28, 2025

Everest Medicines Presents Complete Maintenance Period Data for Etrasimod at ECCO 2025

February 25, 2025

Everest Medicines to Announce Full-Year 2024 Financial Results on March 26, 2025

February 25, 2025

Everest Medicines Announces the Implementation of NEFECON National Reimbursement Drug List Pricing in China for the Treatment for IgA Nephropathy

January 2, 2025

Everest Medicines Announces the Implementation of NEFECON NRDL Pricing in China

January 2, 2025

Everest Medicines Announces the First Prescription of VELSIPITY(R) in the Greater Bay Area

December 19, 2024

Everest Medicines Announces Positive Results in Preliminary Analysis of Phase 1b/2a Clinical Trial of EVER001, a Novel BTK Inhibitor for the Treatment of Primary Membranous Nephropathy

December 4, 2024

← Newer news releases

Decks

The 5 newest of 9 decks. Every deck is listed under its year.